Research
Bacillus coagulans
46 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial investigated Bacillus coagulans Unique IS2 in 144 healthy adults with infrequent bowel movements. The study found a significant increase in bowel movement frequency and improved stool consistency in the Unique IS2 group compared to placebo after 4 weeks. No effects were observed on GI symptoms, quality of life, or gut microbiota composition.
Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial.
RCT of 111 healthy adults in China with functional GI complaints, testing Bacillus coagulans GBI-30, 6086 (BC30) probiotic. BC30 improved GI functions, increasing stool frequency, improving fecal consistency, and reducing constipation, with minor microbiome changes.
Application of novel nosocomial infection prevention and control combined with intestinal probiotics in children with hand, foot and mouth disease.
Randomised case-control study at Hunan Children's Hospital comparing conventional treatment to bacillus coagulans live tablets combined with infection prevention in children with hand, foot and mouth disease. Group 2 showed shorter symptom and fever resolution times, improved immune function, better quality of life, and higher nursing satisfaction compared to Group 1.
High-dose multi-strain Bacillus probiotics enhance treatment and reduce antibiotic usage in children with persistent diarrhea through immune and microbiota modulation.
RCT evaluating high-dose multi-strain Bacillus spore probiotics (LiveSpo DIA30) in children with persistent diarrhea. The probiotic group showed a 3-day shorter recovery period, reduced antibiotic usage by 25%, and significant reductions in pro-inflammatory cytokines. Improvements in gut microbiota composition were also observed.
Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial.
This randomized controlled trial investigated the effectiveness and safety of Bacillus coagulans BCP92 in managing IBS symptoms in 100 participants over 12 weeks. B. coagulans BCP92 significantly improved IBS severity, gastrointestinal symptom frequency, stool consistency, and mental stress relief compared to the control group, with no severe adverse events reported.
Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial.
A randomized, triple-blind, placebo-controlled trial assessed the effects of synbiotics on health-related quality of life in 56 women with PCOS over 12 weeks. Synbiotic supplementation improved emotional, body hair, weight, and infertility domains of PCOSQ-26 and the physical score within SF-12, but showed no significant improvement in the PSS-10 score.
The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study.
RCT evaluating Bacillus coagulans MTCC 5856 (LactoSpore) on functional gas and bloating in 70 adults. Significant improvement in GSRS indigestion scores and global evaluation scores in the probiotic group compared to placebo. No adverse events reported.
The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study.
Double-blind, placebo-controlled trial assessing Bacillus coagulans Unique IS-2 supplementation on protein absorption and muscle strength in resistance-trained males. The probiotic increased plasma-free amino acids and improved leg press and vertical jump power, indicating enhanced muscle power.
Effect of Bacillus coagulans Unique IS2 with Lactulose on Functional Constipation in Adults: a Double-Blind Placebo Controlled Study.
Double-blind randomized study evaluating the efficacy of Bacillus coagulans Unique IS2 with lactulose in treating functional constipation in 150 adults. The combination showed significant improvements in stool frequency and consistency, and reduced sensation of incomplete evacuation, defecation, and abdominal pain compared to lactulose alone.
Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial.
RCT of 80 healthy adults with mild intermittent constipation comparing Bacillus coagulans SNZ 1969 supplementation to placebo for 8 weeks. BC supplementation significantly improved colonic transit time, complete spontaneous bowel movement scores, and bowel discomfort symptom scores, while altering gut microbiota composition.
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial.
This pilot RCT assessed the efficacy and safety of spore-forming probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02) in treating functional dyspepsia. The study found a higher proportion of clinical responders with probiotics compared to placebo, with similar adverse event rates. The probiotics were associated with beneficial immune and microbial changes.
Effect of Bacillius Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy, A Randomized-Controlled Clinical Trial.
RCT of 60 morbidly obese patients undergoing sleeve gastrectomy, comparing a probiotic/prebiotic blend (bacillus coagulans and galactomannans) to placebo. The probiotic/prebiotic group showed greater weight loss at 6 weeks, significant drops in triglycerides, AST, and LDL compared to placebo.
The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study.
Open-label, single-arm pilot study assessing the efficacy and safety of Clostridium butyricum and Bacillus coagulans for Helicobacter pylori eradication. The study found similar eradication rates across groups with no adverse events reported, suggesting potential effectiveness in inhibiting H pylori.
Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study.
Double-blind, placebo-controlled study evaluating the efficacy of Bacillus coagulans Unique IS2 in treating functional constipation in adults. The probiotic group showed a significant increase in bowel movements, improved stool consistency, and relief from symptoms of incomplete evacuation, painful defecation, and abdominal pain compared to placebo.
The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial.
RCT of 53 patients with NAFLD comparing Bacillus coagulans plus inulin supplementation to placebo for 12 weeks. The synbiotic group showed significant reductions in serum alanine aminotransferase, glutamine transaminase, tumor necrosis factor-α, nuclear factor-κB activity, and hepatic steatosis compared to placebo.
Effects of dietary fiber with Bacillus coagulans lilac-01 on bowel movement and fecal properties of healthy volunteers with a tendency for constipation.
Double-blind placebo-controlled randomized trial with 297 healthy Japanese volunteers with a tendency for constipation. The test group receiving Bacillus coagulans lilac-01 and okara powder showed significant improvements in fecal size, sensation of incomplete evacuation, and defecation frequency compared to placebo.
Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial.
RCT evaluating the efficacy of Lactobacillus sporogenes in reducing the incidence and severity of necrotizing enterocolitis (NEC) in very low-birth weight infants. No significant difference in the incidence of death or NEC was found, but feeding intolerance was significantly lower in the probiotics group.
Effect of probiotic on growth performance and digestive enzyme activity of Arbor Acres broilers.
The study investigated the effect of Bacillus coagulans NJ0516 on growth performance and digestive enzyme activity in Arbor Acres broilers. Probiotic supplementation improved growth performance, including final weight and daily weight gain, and increased protease and amylase activities compared to the control group.
Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects: A randomized, double-blind, placebo-control study.
RCT assessing the impact and safety of Bacillus coagulans (LactoSpore) supplementation on gut microbiota composition in 30 healthy Indian adults over 28 days. The study found minimal changes to the gut microbiome, with an increase in beneficial bacteria and no adverse events reported.
Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant].
RCT evaluating Bacillus coagulans LBSC in 38 IBS patients over 80 days. The interventional group showed significant improvement in IBS symptoms and stool consistency compared to placebo, with no serious adverse events.
Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.
RCT investigating the efficacy of B. coagulans Unique IS2 in managing IBS symptoms in adults. 136 patients were randomized to receive either B. coagulans or placebo for 8 weeks. B. coagulans showed significant improvement in abdominal discomfort/pain and bowel movements compared to placebo, with no severe adverse events reported.
A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort.
This RCT evaluated the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend, in managing gastrointestinal discomfort in 60 adults. Significant improvements were observed in various symptoms of GI discomfort with SNZ TriBac compared to placebo, with no adverse events reported.
Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?
RCT comparing low FODMAP diet plus Bacillus coagulans supplementation to low FODMAP diet alone in 50 IBS patients. Significant improvements in IBS symptoms were observed in both groups, with greater improvement in severity score in the probiotic group.
Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study.
Double-blind randomized controlled trial evaluating the efficacy of Bacillus coagulans Unique IS2 in treating Irritable Bowel Syndrome in children aged 4-12 years. The probiotic group showed significant reductions in pain intensity and improvements in stool consistency, abdominal discomfort, and other IBS symptoms compared to placebo.
A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort.
This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and efficacy of Bacillus coagulans LBSC in 60 subjects with acute diarrhea and abdominal discomfort. The probiotic was well-tolerated and effective in improving symptoms and quality of life, with no adverse events reported.
The Consumption of Synbiotic Bread Containing Lactobacillus sporogenes and Inulin Affects Nitric Oxide and Malondialdehyde in Patients with Type 2 Diabetes Mellitus: Randomized, Double-Blind, Placebo-Controlled Trial.
This randomized, double-blind, placebo-controlled trial studied the effects of synbiotic bread containing Lactobacillus sporogenes and inulin on nitric oxide and malondialdehyde levels in 81 patients with type 2 diabetes mellitus. After 8 weeks, synbiotic bread consumption significantly increased plasma nitric oxide and reduced malondialdehyde levels compared to probiotic and control breads, but had no significant effect on other biomarkers or blood pressure.
A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
This randomized double-blind placebo-controlled clinical trial evaluated the efficacy and safety of a combination of simethicone and Bacillus coagulans in treating irritable bowel syndrome (IBS). The study found significant reductions in bloating, discomfort, and pain in the treatment group compared to placebo.
Effects of synbiotic food consumption on glycemic status and serum hs-CRP in pregnant women: a randomized controlled clinical trial.
RCT of 52 pregnant women consuming synbiotic food containing Lactobacillus sporogenes and inulin for 9 weeks. The synbiotic group showed beneficial effects on insulin actions, with significant decreases in serum insulin levels and HOMA-IR, and an increase in QUICKI score, but no effect on FPG and serum hs-CRP concentrations.
Dietary supplementation of probiotics affects growth, immune response and disease resistance of Cyprinus carpio fry.
The study evaluated the effects of dietary supplementation with Bacillus coagulans, Bacillus licheniformis, and Paenibacillus polymyxa on growth, immune response, and disease resistance in Cyprinus carpio fry. Probiotic supplementation improved growth performance, non-specific immunity, and resistance against Aeromonas hydrophila infection, with P. polymyxa showing the most significant benefits.
Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial.
This double-blind randomized cross-over controlled clinical trial investigated the effects of synbiotic food consumption on metabolic profiles, inflammation, and oxidative stress in 62 diabetic patients. The synbiotic food significantly decreased serum insulin and hs-CRP levels, increased plasma total GSH and serum uric acid levels, but had no significant effect on plasma TAC levels.
Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhoea in children.
Double-blind, randomised, placebo-controlled trial assessing the efficacy of Lactobacillus sporogenes (Bacillus coagulans) as a probiotic in children with acute watery diarrhoea. The study found no significant differences in recovery rate, duration, frequency, or volume of diarrhoea between the probiotic and placebo groups.
A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms.
This randomized double-blind placebo-controlled trial evaluated the effects of a Bacillus coagulans-based probiotic on gastrointestinal symptoms in 61 adults with post-prandial intestinal gas-related symptoms. The probiotic group showed significant improvements in abdominal pain and total GSRS scores compared to placebo, with a trend towards improvement in abdominal distension.
Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.
This randomized, double-blind, placebo-controlled pilot study evaluated the effects of Bacillus coagulans GBI-30, 6086 on symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D). The study found that B. coagulans significantly reduced the average number of bowel movements per day compared to placebo in 52 patients with IBS-D.
Evaluation of technological, nutritional, and probiotic survival in gluten‐free composite Synbiotic Vermicelli
The study investigated the physicochemical and sensory attributes of gluten-free vermicelli made from pseudocereals and the survival of B. coagulans IS2 spores in the product. The synbiotic vermicelli showed potential health benefits, with probiotic spores surviving the production and cooking processes at levels adequate for consumer benefits.
Comparison of the effect of regular and probiotic cake (Bacillus coagulans) on salivary pH and Streptococcus mutans count.
Randomized, double-blind, cross-sectional cohort study on 40 healthy volunteers comparing the effects of probiotic cake containing Bacillus coagulans and regular cake on salivary pH and Streptococcus mutans count. No significant difference in S. mutans count was found with probiotic cake, but a significant difference was noted with regular cake. Both cakes caused a drop in salivary pH.
The Effect of 2 Weeks of Inactivated Probiotic Bacillus coagulans on Endocrine, Inflammatory, and Performance Responses During Self-Defense Training in Soldiers.
RCT examining the effect of 2 weeks of inactivated Bacillus coagulans ingestion on performance and inflammatory cytokines during self-defense training in soldiers. No significant changes were found in performance or blood variables, but trends suggested beneficial effects on vertical jump power and inflammatory markers.
Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study
RCT of 40 patients with major depressive disorder and IBS comparing Bacillus coagulans MTCC 5856 to placebo over 90 days. Significant improvements were observed in depression and IBS symptoms, with reductions in inflammatory biomarkers.
Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
Double blind placebo controlled trial of Bacillus coagulans MTCC 5856 in 36 diarrhea predominant IBS patients. The study found significant improvements in clinical symptoms like bloating, vomiting, diarrhea, abdominal pain, and stool frequency, as well as increased quality of life in the B. coagulans group compared to placebo.
Bacillus coagulans GBI-30, 6086 Modulates Faecalibacterium prausnitzii in Older Men and Women.
This double-blind, placebo-controlled crossover study investigated the effects of Bacillus coagulans GBI-30, 6086 (BC30) on gut and immune function in adults aged 65-80. BC30 consumption significantly increased populations of beneficial bacteria and the anti-inflammatory cytokine IL-10, suggesting potential benefits for gut health and immunity.
Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial.
Double-blind placebo-controlled trial of Bacillus coagulans GBI-30, 6086 probiotic in HIV-1-infected persons on antiretroviral therapy. The probiotic was safe, improved chronic gastrointestinal symptoms, and increased the percentage of blood CD4(+) T cells compared to placebo.
Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.
This randomized, double-blind, placebo-controlled trial evaluated the effects of Bacillus coagulans GBI-30, 6086 on rheumatoid arthritis symptoms in 45 patients. The probiotic showed statistically significant improvements in pain scale, patient global assessment, self-assessed disability, and reduction in CRP compared to placebo, with no treatment-related adverse events.
Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.
This randomized, double-blind, placebo-controlled trial evaluated the effects of Bacillus coagulans GBI-30, 6086 on IBS symptoms in 44 subjects over 8 weeks. The probiotic group showed statistically significant improvements in abdominal pain and bloating compared to baseline, suggesting it may be a safe and effective option for IBS symptom relief.
A patented strain of Bacillus coagulans increased immune response to viral challenge.
A controlled study evaluated the effects of the patented GanedenBC30 probiotic (Bacillus coagulans GBI-30, 6086) on the immune system in healthy adults. The use of GanedenBC30 significantly increased T-cell production of TNF-alpha in response to adenovirus and influenza A exposure, suggesting it may enhance immune response to certain viral infections.
Gluten-Free Synbiotic Pseudocereals Pasta: Evaluation of Technological, Nutritional, Sensory, and Probiotic Characteristics
The study evaluates gluten-free synbiotic pasta made from pseudocereal blends with B. coagulans Unique IS2 spores. The pasta showed enhanced nutritional quality, antioxidant activity, and fiber content compared to wheat pasta. B. coagulans spores survived pasta production and cooking, indicating potential health benefits.
Synbiotic Supplementation Containing Whole Plant Sugar Cane Fibre and Probiotic Spores Potentiates Protective Synergistic Effects in Mouse Model of IBD
The study assessed the effects of synbiotic supplementation with Bacillus coagulans spores and whole plant sugar cane fibre in a mouse model of IBD. Synbiotic supplementation improved disease activity index and histological scores, modulated serum cytokine levels, and increased short-chain fatty acids more effectively than individual components.
Effect of prebiotics on the fecal microbiota of elderly volunteers after dietary supplementation of Bacillus coagulans GBI-30, 6086.
In vitro study assessing the effects of Bacillus coagulans GBI-30, 6086 (GanedenBC30) supplementation on fecal microbiota from elderly volunteers. The study found that BC30 consumption, followed by prebiotic supplementation, increased populations of beneficial bacteria and organic acid production compared to placebo.